News and Announcements
Analytica Investor Update Webcast: Link to Recording
- Published April 08, 2016 4:57PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
8th April 2016
Analytica Ltd (ASX:ALT) has released a recording of the investor webinar held on Thursday 7th April at 9am AEST to discuss the company’s future strategy and planning for the year ahead.
During the webinar, Analytica CEO Geoff Daly, VP of Global Marketing Megan Henken and chairman Michael Monsour discussed Analytica gaining regulatory approval in the US and European markets for the Pericoach®, the company’s primary sales and marketing focuses, including gathering clinical trial data and evidence to support a deal with a large sales and marketing multinational, and directly answered shareholder feedback in a live Q&A session.
A copy of the webinar recording can be accessed by clicking the button below.
Or through the Analytica webpage at:
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
